A three-step serum-free protocol for the robust generation of monocyte-derived dendritic cells from human hematopoietic stem/progenitor cells.

IF 4.3 3区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Bioprocess and Biosystems Engineering Pub Date : 2026-10-12 DOI:10.1007/s00449-026-03441-4

Tsung-Yu Tseng, Hsing-Fen Tsai, Yun Chen, Keng-Fu Hsu, Wei-Lun Huang, Chieh-Tsung Lo, Po-Ming Wu, Chao-Ling Yao

{"title":"A three-step serum-free protocol for the robust generation of monocyte-derived dendritic cells from human hematopoietic stem/progenitor cells.","authors":"Tsung-Yu Tseng, Hsing-Fen Tsai, Yun Chen, Keng-Fu Hsu, Wei-Lun Huang, Chieh-Tsung Lo, Po-Ming Wu, Chao-Ling Yao","doi":"10.1007/s00449-026-03441-4","DOIUrl":null,"url":null,"abstract":"<p><p>Dendritic cells (DCs) and their monocyte precursors are rare in peripheral blood, which limits their use in immunotherapy. Although hematopoietic stem/progenitor cells (HSPCs) provide an alternative source, they are even less abundant in vivo. To address this limitation and compensate for apoptosis during the generation of DCs from monocytes, we developed a three-step serum-free protocol (culture system) that combines HSPC expansion with sequential differentiation. The protocol comprises a 7-day HSPC expansion phase, a 14-day monocyte induction phase, and a 7-day DC generation phase-5 days of differentiation followed by 2 days of maturation with either tumor necrosis factor-α or lipopolysaccharide. Cell quantification revealed that the system generated approximately 5,000 monocytes and 50 DCs from a single HSPC. The generated DCs expressed the key surface markers CD40 and CD209 and exhibited antigen uptake capacity comparable to that of native CD14⁺ monocyte-derived DCs. Overall, this system provides a reproducible and scalable platform for studying DC biology and supports applications in preclinical and translational immunotherapy research.</p>","PeriodicalId":9024,"journal":{"name":"Bioprocess and Biosystems Engineering","volume":" ","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioprocess and Biosystems Engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s00449-026-03441-4","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Dendritic cells (DCs) and their monocyte precursors are rare in peripheral blood, which limits their use in immunotherapy. Although hematopoietic stem/progenitor cells (HSPCs) provide an alternative source, they are even less abundant in vivo. To address this limitation and compensate for apoptosis during the generation of DCs from monocytes, we developed a three-step serum-free protocol (culture system) that combines HSPC expansion with sequential differentiation. The protocol comprises a 7-day HSPC expansion phase, a 14-day monocyte induction phase, and a 7-day DC generation phase-5 days of differentiation followed by 2 days of maturation with either tumor necrosis factor-α or lipopolysaccharide. Cell quantification revealed that the system generated approximately 5,000 monocytes and 50 DCs from a single HSPC. The generated DCs expressed the key surface markers CD40 and CD209 and exhibited antigen uptake capacity comparable to that of native CD14⁺ monocyte-derived DCs. Overall, this system provides a reproducible and scalable platform for studying DC biology and supports applications in preclinical and translational immunotherapy research.

查看原文本刊更多论文

从人造血干细胞/祖细胞稳健生成单核细胞来源的树突状细胞的三步无血清方案

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioprocess and Biosystems Engineering 工程技术-工程：化工

CiteScore

7.90

自引率

2.60%

发文量

147

审稿时长

2.6 months

期刊介绍： Bioprocess and Biosystems Engineering provides an international peer-reviewed forum to facilitate the discussion between engineering and biological science to find efficient solutions in the development and improvement of bioprocesses. The aim of the journal is to focus more attention on the multidisciplinary approaches for integrative bioprocess design. Of special interest are the rational manipulation of biosystems through metabolic engineering techniques to provide new biocatalysts as well as the model based design of bioprocesses (up-stream processing, bioreactor operation and downstream processing) that will lead to new and sustainable production processes. Contributions are targeted at new approaches for rational and evolutive design of cellular systems by taking into account the environment and constraints of technical production processes, integration of recombinant technology and process design, as well as new hybrid intersections such as bioinformatics and process systems engineering. Manuscripts concerning the design, simulation, experimental validation, control, and economic as well as ecological evaluation of novel processes using biosystems or parts thereof (e.g., enzymes, microorganisms, mammalian cells, plant cells, or tissue), their related products, or technical devices are also encouraged. The Editors will consider papers for publication based on novelty, their impact on biotechnological production and their contribution to the advancement of bioprocess and biosystems engineering science. Submission of papers dealing with routine aspects of bioprocess engineering (e.g., routine application of established methodologies, and description of established equipment) are discouraged.